FNA Quote, Financials, Valuation and Earnings

Alphatec Holdings has a net margin of -15.5% compared to Paragon 28's net margin of -18.85%. Paragon 28's return on equity of -36.38% beat Alphatec Holdings's return on equity of -691.37%.

Paragon 28 has a consensus price target of $14.50, signalling upside risk potential of 11.45%. On the other hand Alphatec Holdings has an analysts' consensus of $18.04 which suggests that it could grow by 81.69%. Given that Alphatec Holdings has higher upside potential than Paragon 28, analysts believe Alphatec Holdings is more attractive than Paragon 28.

Paragon 28 has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alphatec Holdings has a beta of 1.388, suggesting its more volatile than the S&P 500 by 38.793%.

Paragon 28 has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alphatec Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Paragon 28 pays -- of its earnings as a dividend. Alphatec Holdings pays out -- of its earnings as a dividend.

Paragon 28 quarterly revenues are $71.7M, which are smaller than Alphatec Holdings quarterly revenues of $176.8M. Paragon 28's net income of -$11.1M is higher than Alphatec Holdings's net income of -$33.3M. Notably, Paragon 28's price-to-earnings ratio is -- while Alphatec Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Paragon 28 is 4.23x versus 2.32x for Alphatec Holdings. Usually stocks with elevated PS ratios are considered overvalued.

electroCore has a net margin of -15.5% compared to Paragon 28's net margin of -45.81%. Paragon 28's return on equity of -36.38% beat electroCore's return on equity of -147.07%.

Paragon 28 has a consensus price target of $14.50, signalling upside risk potential of 11.45%. On the other hand electroCore has an analysts' consensus of $25.20 which suggests that it could grow by 215%. Given that electroCore has higher upside potential than Paragon 28, analysts believe electroCore is more attractive than Paragon 28.

Paragon 28 has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison electroCore has a beta of 0.244, suggesting its less volatile than the S&P 500 by 75.612%.

Paragon 28 has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. electroCore offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Paragon 28 pays -- of its earnings as a dividend. electroCore pays out -- of its earnings as a dividend.

Paragon 28 quarterly revenues are $71.7M, which are larger than electroCore quarterly revenues of $7M. Paragon 28's net income of -$11.1M is lower than electroCore's net income of -$3.2M. Notably, Paragon 28's price-to-earnings ratio is -- while electroCore's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Paragon 28 is 4.23x versus 2.38x for electroCore. Usually stocks with elevated PS ratios are considered overvalued.

Integra Lifesciences Holdings has a net margin of -15.5% compared to Paragon 28's net margin of 4.39%. Paragon 28's return on equity of -36.38% beat Integra Lifesciences Holdings's return on equity of -0.45%.

Paragon 28 has a consensus price target of $14.50, signalling upside risk potential of 11.45%. On the other hand Integra Lifesciences Holdings has an analysts' consensus of $26.25 which suggests that it could grow by 16.72%. Given that Integra Lifesciences Holdings has higher upside potential than Paragon 28, analysts believe Integra Lifesciences Holdings is more attractive than Paragon 28.

Paragon 28 has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Integra Lifesciences Holdings has a beta of 1.229, suggesting its more volatile than the S&P 500 by 22.861%.

Paragon 28 has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integra Lifesciences Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Paragon 28 pays -- of its earnings as a dividend. Integra Lifesciences Holdings pays out -- of its earnings as a dividend.

Paragon 28 quarterly revenues are $71.7M, which are smaller than Integra Lifesciences Holdings quarterly revenues of $442.6M. Paragon 28's net income of -$11.1M is lower than Integra Lifesciences Holdings's net income of $19.4M. Notably, Paragon 28's price-to-earnings ratio is -- while Integra Lifesciences Holdings's PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Paragon 28 is 4.23x versus 1.08x for Integra Lifesciences Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Zimmer Biomet Holdings has a net margin of -15.5% compared to Paragon 28's net margin of 11.84%. Paragon 28's return on equity of -36.38% beat Zimmer Biomet Holdings's return on equity of 7.21%.

Paragon 28 has a consensus price target of $14.50, signalling upside risk potential of 11.45%. On the other hand Zimmer Biomet Holdings has an analysts' consensus of $121.85 which suggests that it could grow by 10.04%. Given that Paragon 28 has higher upside potential than Zimmer Biomet Holdings, analysts believe Paragon 28 is more attractive than Zimmer Biomet Holdings.

Paragon 28 has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Zimmer Biomet Holdings has a beta of 1.037, suggesting its more volatile than the S&P 500 by 3.696%.

Paragon 28 has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zimmer Biomet Holdings offers a yield of 0.87% to investors and pays a quarterly dividend of $0.24 per share. Paragon 28 pays -- of its earnings as a dividend. Zimmer Biomet Holdings pays out 21.69% of its earnings as a dividend. Zimmer Biomet Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Paragon 28 quarterly revenues are $71.7M, which are smaller than Zimmer Biomet Holdings quarterly revenues of $2B. Paragon 28's net income of -$11.1M is lower than Zimmer Biomet Holdings's net income of $239.5M. Notably, Paragon 28's price-to-earnings ratio is -- while Zimmer Biomet Holdings's PE ratio is 24.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Paragon 28 is 4.23x versus 2.94x for Zimmer Biomet Holdings. Usually stocks with elevated PS ratios are considered overvalued.